Armodafinil

Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007.

Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition associated with schizophrenia, and excessive sleepiness and fatigue in conditions such as Parkinson's disease and cancer.

Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil.